NY-EMPIRE-STATE-REALTY
A 270-foot-long dragon has landed in the center of New York City – atop the iconic Empire State Building (ESB). In partnership with Max, ESB has acknowledged that Vhagar the Dragon has coiled herself around its mast just as ESB and Max cap off their weeklong “House of the Dragon” takeover.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240616631517/en/
Empire State Building Debuts 270-Foot Vhagar the Dragon Coiled Around the Building’s Mast, in Partnership with Max (Photo: Business Wire)
The best views of Vhagar are in Manhattan from the south of ESB, and unique selfie moments are available from ESB itself where she scans for prey with her huge head extended over the southern deck of ESB’s 86th Floor Observatory. ESB’s lights have been set so fans can witness a series of dynamic light shows which feature the dragon against schemes of gold, green, and red.
“Just after the Empire State Building pledged its allegiance to the King, Vhagar descended upon the heart of New York City and has claimed the mast of the ‘World’s Most Famous Building’ as her perch,” said ESRT Chairman and CEO Tony Malkin. “Citizens of Westeros can now sit in the Iron Throne at the Observatory’s grand staircase and then rise to the 86th Floor to face the colossal beast up close as they take in the unmatched, 360-degree views from our world-famous Observatory – Tripadvisor’s #1 attraction in the United States.”
Affixed by more than 153 rigging points, Vhagar is made up of 1,700 total patterns and 600,000 inches of sewn seams. The giant dragon was created in partnership with creative agency Giant Spoon and fabricated by Bigger Than Life Advertising Inc. The company’s President Mark Bachman was a manager on the Empire State Building’s King Kong installation in 1983.
The “House of the Dragon” takeover included a photo opportunity with the iconic Iron Throne, a visit from the “House of the Dragon” cast, and an interactive photo booth on the 80th Floor. This partnership with Max is just one of several recent events at the Empire State Building which have garnered global attention, which include partnerships with Mercedes-AMG Petronas F1 x WhatsApp, Outward Bound, and “Star Wars.”
The Empire State Building Observatory recently underwent a $165 million reimagination that included the addition of a dedicated visitor entrance, an immersive museum with nine galleries, brand-new, bespoke Observatory Host uniforms, and a new 102nd Floor Observatory with unmatched views. The reimagined Observatory Experience has been voted the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years.
Tickets to see the dragon at the Empire State Building Observatory can be purchased here. Text CONNECT to 274-16 to receive real-time information about the Empire State Building’s tower lights.
Hi-res imagery and video of all elements of the House of the Dragon takeover can be found here.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
About House of the Dragon
Based on George R.R. Martin’s “Fire & Blood,” the series, set 200 years before the events of “Game of Thrones,” tells the story of House Targaryen. Co-Creator/Executive Producer George R.R. Martin; Co-Creator/Showrunner/Executive Producer, Ryan Condal; Executive Producers Sara Hess, Alan Taylor, Melissa Bernstein, Kevin de la Noy, Loni Peristere, Vince Gerardis. Season two returning cast includes Matt Smith, Olivia Cooke, Emma D’Arcy, Eve Best, Steve Toussaint, Fabien Frankel, Ewan Mitchell, Tom Glynn-Carney, Sonoya Mizuno, and Rhys Ifans. Additional returning cast includes Harry Collett, Bethany Antonia, Phoebe Campbell, Phia Saban, Jefferson Hall, and Matthew Needham. New season two cast are Abubakar Salim as Alyn of Hull, Gayle Rankin as Alys Rivers, Freddie Fox as Ser Gwayne Hightower, Simon Russell Beale as Ser Simon Strong, Clinton Liberty as Addam of Hull, Jamie Kenna as Ser Alfred Broome, Kieran Bew as Hugh, Tom Bennett as Ulf, Tom Taylor as Lord Cregan Stark, and Vincent Regan as Ser Rickard Thorne.
Source: Empire State Realty Trust
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240616631517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom